Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-03

Clinical Trial Update: Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AIN457 (secukinumab) for active non-infectious uveitis was terminated, with safety and efficacy results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Uveitis | Phase 3 | Status: TERMINATED | Results posted: 2015-11-03